​

NewAmsterdam Pharma (NAMS) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

NewAmsterdam Pharma Revenue Highlights

Latest Revenue (Y)

$45.56M

Latest Revenue (Q)

$2.98M

Main Segment (Y)

License Revenue

NewAmsterdam Pharma Revenue by Period

NewAmsterdam Pharma Revenue by Year

DateRevenueChange
2024-12-31$45.56M257.00%
2023-12-31$12.76M-86.69%
2022-12-31$95.91M100.00%
2021-12-31-100.00%
2020-12-31--

NewAmsterdam Pharma generated $45.56M in revenue during NA 2024, up 257.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

NewAmsterdam Pharma Revenue by Quarter

DateRevenueChange
2025-03-31$2.98M-76.68%
2024-12-31$12.77M-56.13%
2024-09-30$29.11M1177.36%
2024-06-30$2.28M62.67%
2024-03-31$1.40M-12.14%
2023-12-31$1.59M-15.06%
2023-09-30$1.88M19.31%
2023-06-30$1.57M-80.22%
2023-03-31$7.96M474.62%
2022-12-31$1.38M-75.36%
2022-09-30$5.62M-87.98%
2022-06-30$46.75M-
2022-03-31$46.75M100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--

NewAmsterdam Pharma generated $2.98M in revenue during Q1 2025, up -76.68% compared to the previous quarter, and up 186.76% compared to the same period a year ago.

NewAmsterdam Pharma Revenue Breakdown

NewAmsterdam Pharma Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 22
License Revenue$93.50M

NewAmsterdam Pharma's latest annual revenue breakdown by segment (product or service), as of Dec 22: License Revenue (100.00%).

Quarterly Revenue by Product

Product/ServiceJun 23
License Revenue$4.56M

NewAmsterdam Pharma's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: License Revenue (100.00%).

NewAmsterdam Pharma Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ACLXArcellx$107.94M$8.13M
KYMRKymera Therapeutics$47.07M$11.48M
NAMSNewAmsterdam Pharma$45.56M$2.98M
ARWRArrowhead Pharmaceuticals$3.55M$542.71M
CRNXCrinetics Pharmaceuticals$1.04M$361.00K
AKROAkero Therapeutics--
PTGXProtagonist Therapeutics-$28.32M
SLNOSoleno Therapeutics-$32.66M
VKTXViking Therapeutics--
CGONCG Oncology-$52.00K

NAMS Revenue FAQ

What is NewAmsterdam Pharma’s yearly revenue?

NewAmsterdam Pharma's yearly revenue for 2024 was $45.56M, representing an increase of 257.00% compared to 2023. The company's yearly revenue for 2023 was $12.76M, representing a decrease of -86.69% compared to 2022. NAMS's yearly revenue for 2022 was $95.91M, representing an increase of 100.00% compared to 2021.

What is NewAmsterdam Pharma’s quarterly revenue?

NewAmsterdam Pharma's quarterly revenue for Q1 2025 was $2.98M, a -76.68% decrease from the previous quarter (Q4 2024), and a 112.56% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $12.77M, a -56.13% decrease from the previous quarter (Q3 2024), and a 700.98% increase year-over-year (Q4 2023). NAMS's quarterly revenue for Q3 2024 was $29.11M, a 1177.36% increase from the previous quarter (Q2 2024), and a 1450.69% increase year-over-year (Q3 2023).

What is NewAmsterdam Pharma’s revenue growth rate?

NewAmsterdam Pharma's revenue growth rate for the last 3 years (2022-2024) was -52.49%, and for the last 5 years (2020-2024) was 0%.

What are NewAmsterdam Pharma’s revenue streams?

NewAmsterdam Pharma's revenue streams in c 22 are License Revenue

What is NewAmsterdam Pharma’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of NewAmsterdam Pharma was License Revenue. This segment made a revenue of $93.5M, representing 100.00% of the company's total revenue.